Navigation Links
Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
Date:11/29/2007

JERUSALEM, November 29 /PRNewswire/ -- Jerusalem Global Ventures today announced that it will soon be launching JGV Growth Equity Fund, L.P., a $200 million fund. The Fund will invest in private Israeli related technology companies that are on a trajectory to IPO within three years and have a proven business model. First closing is scheduled for April 2008.

Dr. Shlomo Kalish, who founded Jerusalem Global in 1994, notes that, "Unlike the early stage VC investment model, where one expects multiple write-offs for every 'home run', this Fund's business model should produce quicker turnaround of money, lower risk, and more predictable returns." In 2007, Dr. Kalish was the only Israeli in the Top 50 of the Forbes Midas list.

Jerusalem Global currently manages two sector funds launched in 1999. When compared to peers of the same vintage, one of those funds is at the top in terms of both cash distribution and IRR. Jerusalem Global's spokesman said, "We believe the record of the second fund will be as good or better when the remaining portfolio companies are exited."

Dr. Yoseph Linde, who co-managed the prior Funds, commented, "Over the last several years, in the course of making investments for our early-stage VC fund, we were offered numerous opportunities to invest in late-stage technology companies. Although we rejected most of these offers as they did not fit our primarily early stage focus, we did make two such investments resulting in two successful exits. Our portfolio company, Mellanox, which had a successful IPO earlier this year, would be a perfect example of companies we'd fund." Dr. Linde was a successful serial entrepreneur before joining Jerusalem Global Ventures.

The Fund expects to invest $5-20 million in companies which late-stage financing needs of $10-50 million. Dr. Kalish said, "Think of this Fund as a barbell. On one end we have foreign financial institutions that do not have staff on the ground in Israel but have expressed interest in co-investing with us. On the other end we have investment banks that would like to establish a strategic relationship in order to help prepare our portfolio companies for an IPO. The Fund is the connecting rod in the middle, using the manager's network and expertise to source and invest in quality deals."

Dr. Kalish added, "There are some interesting things going on in Israeli technology. The number of private companies with revenue of more than $10 million has exploded, and we see more in the pipeline. Yet, there is still pressure for such firms to exit too early. This Fund will help successful companies bridge that gap and get to a point where they can realize their full value."

A number of investors in the prior fund have committed to this Fund. In addition, Jerusalem Global will be marketing the Fund to major financial institutions, fund of funds, university endowments, and pension funds.

About Jerusalem Global Ventures

Jerusalem Global began in 1994 and was soon recognized as the leading technology investment bank in Israel. It produced an IRR to investors of 84%, and underwrote some of the largest offerings in Israel, including Galileo and Creo. The prior fund, mentioned above, was begun in 1999 and also had some notable exits, including Mellanox and Kashya.

Drs. Kalish and Linde, the senior investment professionals, have been together over nine years. Rounding out the investment team are Ranan Grobman, who has been with the Firm for five years, and Shlomo Caine, former Managing Director of Intel Capital (Israel), who has joined as a Venture Partner. Robbie Citron is the CFO, and Paul Lowenstein has joined the firm as Director of Investor Relations.

Contact:

Dr. Shlomo Kalish or Paul Lowenstein, through http://www.jgv.com, or at +972-2-649-0750.


'/>"/>
SOURCE Jerusalem Global Ventures Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
3. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
4. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
7. Jazz Pharmaceuticals to Present at UBS Global Life Sciences Conference
8. A Large-Scale Research Project by a Dutch Consortium Addressing a Global Problem
9. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
10. Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference
11. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... ... May 18, 2017 , ... Lajollacooks4u has added ... is a two-hour team-building package designed for groups of 10-30 people. Guests ... which include items, such as Blackened Shrimp with Edamame Salad, Pizza Rolls with ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... psychonneuroendocrine stress expertise, and further enhances its scientific power by providing investigators ... Granger, Ph.D., has agreed to join the scientific advisory board. “We are ...
(Date:5/18/2017)... , ... May 17, 2017 , ... ... equipment for varying industries, including food and dairy, munitions, and pharmaceutical/biotech, recently introduced ... safety and ease of use. The improvement in technology comes on the heels ...
(Date:5/18/2017)... ... May 18, 2017 , ... When James Sherley, was notified earlier this year that ... Brands for the Year 2017 by The Silicon Review , he was not surprised ... progress increasing Asymmetrex’s value, but this recognition by Silicon Valley was particularly meaningful. Our ...
Breaking Biology Technology:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
Breaking Biology News(10 mins):